News Releases & Events

News Releases & Events 2018

• 01/09 Medifocus, Inc. Expands its Reach into the Israeli Market with Amos Gazit Ltd for Its Prolieve® Thermodilatation for BPH Therapy and Announces Significant Debt Conversion into Shares

News Releases & Events 2017

• 08/28 Medifocus, Inc. Announces Significant Improvement in Operating Results for the Fiscal Year Ended March 31, 2017 with Successful Expansion of Prolieve® Global Market & Launching of Prolieve® Prostatitis Study

• 03/16 Medifocus, Inc. Announces First Ever Quarterly Operating Profit and Significant Improvement in Operating Results for the Nine Months Ended December 31, 2016

News Releases & Events 2016

• 10/03 Medifocus Inc. Announces Appointment of New Chief Executive Officer

• 09/14 Medifocus Inc. Announces Election of Directors and Financial Results for the Quarter Ended June 30 2016

• 01/13 Medifocus, Inc. Signs Research & Development and Manufacturing Agreement for Its Patented Technology of Heat-Activated and Tumor Targeted Immunotherapy and Gene Therapy

• 01/11 Medifocus, Inc. Announces the Engagement of Tanaka Kapec Design Group, Inc. as Lead Designer of Next Generation of Prolieve® Thermodilatation System

News Releases & Events 2015

• 12/14 Medifocus, Inc. Announces Closing of First Tranche of Units Offering

• 12/07 Medifocus, Inc. Announces Financial Results for the Six Months Ending September 30, 2015

• 10/19 Medifocus, Inc. Announces Presenting Papers at Biotechnology and Information Technology’s 5th Annual Symposium in Beijing, October 20-22, 2015

• 10/15 Medifocus, Inc. Announces Exclusive Agreement With Major Academic Medical Center to License Technology to Develop Heat-Activated and Tumor-Targeted Immunotherapy and Gene Therapy

• 09/30 Medifocus, Inc. Announces Major Milestone of 100,000 Prolieve(R) Treatments

• 09/28 Medifocus, Inc. Announces Units Offering

• 06/16 Medifocus, Inc. Appoints Christopher Kaplan to Its Strategic Advisory Board

• 06/04 Medifocus, Inc. Appoints Joseph M. Chalil to Its Strategic Advisory Board

• 05/27 Medifocus, Inc. Announces Option Agreement with Major Academic Medical Center to License Technology to Develop Heat Activated and Tumor Targeted Immunotherapy

• 05/12 Medifocus, Inc. Announces Closes Equity Offering

• 03/27 Medifocus, Inc. Announces Equity Offering

• 03/24 Medifocus, Inc. Announces Financial Results for the Nine Months Ending December 31, 2014

News Releases & Events 2014

• 12/15 Medifocus, Inc. Obtains Two Newly Allowed Canadian Patents on the Prevention and Safety for the Treatment for Breast Cancer

• 12/5 Medifocus, Inc.’s Technology Featured in a Mediaplanet Sponsored Insert in “USA Today” on Breast Cancer


• 11/25 Medifocus Inc. Announces Medifocus, Inc. Launches Advertising and Marketing Campaign to Increase Shareholder Awareness of Its Breast Cancer Technology

• 11/19 Medifocus Inc. Announces Medifocus Inc.’s Form 20-F Registration Statement Becomes Effective Immediately

• 11/07 Medifocus Inc. Announces Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014

• 10/23 Medifocus Inc. Announces Its Sponsorship at the VM Medical 20th Anniversary Breast Cancer Conference October 23rd

• 09/15 Medifocus Inc. Announces Closing of Private Placement September 15, 2014

• 07/30 Announces Financial Results for the Fiscal Year and Fiscal Fourth Quarter Ending March 31, 2014

• 07/09 Announces Medifocus, Inc. Is Issued New U.S. Patent for Thermoactivated Drugs and Gene Products

• 07/08 Announces Medifocus, Inc. Featured in Article in BioTuesdays

• 05/27 Medifocus, Inc. to Present at the SeeThruEquity 3rd Annual Microcap Investor Conference and the Third Annual Marcum MicroCap Conference

• 04/04 Medifocus, Inc. to Be Featured on BNN & Fox Business News Network on April 6, 2014

• 03/17 Expands its Reach into the Asia Pacific Market with the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC

• 03/12 Announces Clinical Presentation at 24th Annual Interdisciplinary Breast Center Conference

• 03/11 Announces $2 Million Second Tranche Closing of $6 Million Convertible Debenture Financing

• 03/06 Announces Financial Results for the Third Fiscal Quarter and Nine Months Ending December 31, 2013

• 03/06 Obtains Newly Allowed European Patent Office EPO Patent

News Releases & Events 2013

• 12/18 Announces Closing of First Tranche of Debenture Financing

• 12/11 Announces VM Medical Center in Montreal Has Successfully Treated Its First Patient

• 12/4 Announces Record 294% Increase in Q2/FY 2014 Revenue

• 11/12 Announces Joint Venture with Ideal Concept Group, Ltd

• 08/29 Announces Revenue and Results of Operations for Fiscal First Quarter 2014

• 08/09 Announces the Initiation of Its Principal Investigational Site in Canada

• 07/31 New US Patent Covering the Use of Heat

• 07/29 Medifocus Inc. Announces Revenues for Year Ended March 31, 2013

• 07/24 Announces Maxim Group as Financial Advisor and Investment Banker

• 07/09 Announces DTC Eligibility of Stock

• 04/24 Announces Extension of Warrants

• 03/18 Announces Completion of Shares

• 02/25 New US Patent

• 02/14 Awarded Position on TSX

• 02/06 Launch of New Website

• 01/23 Acceleration of Prolieve Rollout

• 01/14 Closing of Private Placement

News Releases & Events 2012

• 12/17 Stock & Share Announcement

• 12/11 Increase in Size of Units Offering

• 12/06 Election & Reports First Revenue

• 11/30 Announces Units Offering

• 11/13 Extension of Warrants

• 11/1 Princeton Research: Money Info Show, November 1, 2012, Interview with Grant Walsh, Chairman of Medifocus, Inc.

• 10/22 Medifocus Inc. to Attend the 23rd Video Urology World Congress in Hong Kong on November 9-11: Sees Tremendous Opportunity in Asia for the Marketing of Prolieve(R)

• 10/15 Medifocus Inc. Chairman Grant Walsh Interviewed on the Stock Legends Radio Show

• 10/10 Cohen Independent Research Initiates Coverage on Medifocus Inc. With a Strong Buy Recommendation

• 10/10 Cohen Independent Research Report on Medifocus, Inc.

• 10/9 Medifocus Inc. Retains Consulting for Strategic Growth to Implement a Strategic Investor Relations & Public Relations Program

• 10/4 Medifocus Inc. to Attend Two Upcoming Regional American Urological Association (AUA) Meetings to Promote the Prolieve(R) Device System

• 09/27 Update on the Prolieve(R) Acquisition and the Hiring of the Prolieve(R) Management Team

• 09/24 S&P Capital IQ Initiates Coverage on Medifocus, Inc. in Standard & Poor’s Factual Stock Reports

• 07/25 Medifocus Inc. Completes Purchase of Prolieve(R) for the Treatment of Benign Prostatic Hyperplasia (BPH)

• 06/26 Acquisition of Prolieve(R) Device for Treatment of Benign Prostatic Hyperplasia from Boston Scientific

• 06/21 Closing of Private Placement Medifocus Inc.